Coloplast A/S Class B

Coloplast A/S Class B

75.40
USD
+0.79
(+1.06%)
2.07EPS
29.99P/E
13.99BMarket Cap
Feb 09Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
58.96
65.83
69.35
73.18
77.52
84.5
87.22
91.29
106.25
113.74
120.19
- -
128.4
128.51
Basic EPS, GAAP
11.34
4.25
14.85
17.89
18.12
18.24
19.74
22.67
22.15
22.21
22.46
- -
13.64
13.65
Free Cash Flow per Basic Share
12.41
12.87
11.24
12.09
17.4
17.53
18.01
15.62
18.65
13.86
6.31
- -
28.55
28.58
Dividend per Share
11.01
12
12.52
13.5
15.49
16.01
16.99
18
19.02
19.72
20.99
- -
22.99
23.02
Book Value per Share
29.84
22.27
23.94
28.05
30.22
32.54
34.82
38.38
39.06
77
79.62
- -
63.42
63.42
Tangible Book Value per Share
22.81
15.12
17.34
17.23
18.36
20.77
23.71
21.23
-68.18
-62.12
-54.98
- -
-55.52
-55.52
Basic Weighted Avg Shares
211
211
212
212
212
212
213
213
213
215
225
225
225
225
Sales/Revenue/Turnover
12,428
13,909
14,681
15,528
16,449
17,939
18,544
19,426
22,579
24,500
27,030
- -
28,941
28,941
Operating Margin (%)
33.37
32.6
33.01
32.35
30.95
30.97
31.57
32.71
30.6
27.94
26.96
- -
25.73
25.73
Depreciation Expense
426
485
528
611
625
651
851
792
930
1,069
1,290
- -
4,429
4,429
Net Income, GAAP
2,390
899
3,143
3,797
3,845
3,873
4,197
4,825
4,706
4,783
5,052
- -
3,074
3,074
Effective Tax Rate (%)
25.1
27.79
23
23.29
23.24
22.97
23.22
22.59
23.19
20.61
21
- -
20.14
20.14
Profit Margin (%)
19.23
6.46
21.41
24.45
23.38
21.59
22.63
24.84
20.84
19.52
18.69
- -
10.62
10.62
Working Capital
2,518
1,187
855
769
882
1,417
1,510
680
1,436
-6,374
240
- -
-3,514
-3,514
LT Debt
- -
- -
1
98
91
134
430
449
16,855
12,222
17,291
- -
14,454
14,454
Total Equity
6,283
4,706
5,068
5,952
6,418
6,913
7,406
8,168
8,292
17,299
17,942
- -
14,292
14,292
Return on Invested Capital (%)
32.42
18.84
61.4
57.36
46.98
44.88
46.99
43.76
24.74
15.53
13.99
- -
- -
- -
Return on Capital (%)
36.1
16.15
62.39
59.94
50.76
48.78
48.86
48.19
25.49
16.56
14.67
- -
- -
- -
Return on Common Equity (%)
36.62
16.36
64.31
68.91
62.17
58.11
58.62
61.96
57.18
37.38
28.67
- -
- -
- -

Capital Structure

DKK

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2,232
2,879
7,064
LT Borrowings
21,340
20,207
13,637
LT Finance Leases
656
717
817
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
225
225
225
Market Capitalization
97,260
83,886
92,256

Working Capital

DKK

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
10,453
10,397
9,951
Cash, Cash Equivalents & STI
1,067
817
511
Accounts Receivable, Net
4,587
4,667
4,657
Inventories
3,942
4,131
4,063
Total Current Liabilities
5,979
6,660
13,465
Payables & Accruals
- -
- -
- -
ST Debt
2,232
2,879
7,064
Deferred Revenue
- -
- -
- -

Growth Rates

DKK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

DKK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6,606
6,586
6,885
6,953
27,030
2025
7,026
6,930
6,958
- -
- -
2026
7,043
7,084
7,355
7,459
28,941

Quarterly Earnings Per Share

DKK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5.4
5.57
5.67
5.84
22.46
2025
4.64
4.05
3.57
- -
- -
2026
6.21
-4.31
6.49
5.26
13.64

Quarterly Dividends Per Share

DKK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
16.01
- -
5
- -
20.99
2025
17.03
- -
5
- -
- -
2026
18.03
- -
5
- -
22.99

Company Description

CEO
Gavin Wood
Full Time Employees
17,524
Sector
Health technology
Industry
Medical specialties
Address
Holtedam 1 Humlebaek ZE Denmark 3050
IPO Date
Jan 1, 1983
Business
Coloplast A/S develops manufactures and markets medical devices and services for intimate healthcare needs including ostomy urology continence wound care bowel care voice and respiratory care and interventional urology; its core products encompass ostomy bags and accessories such as Sensura Mio pouches baseplates and convexity solutions; intermittent catheters including the Luja catheter; bowel management systems for transanal irrigation; voice and respiratory care devices for laryngectomy and tracheostomy patients; advanced wound dressings and biologics through subsidiaries like Kerecis; and interventional urology solutions for men's health with upcoming Intibia for women's health pending FDA approval. Founded in 1957 and headquartered in Humlebæk Denmark the company employs over 14000 people operates sales in more than 50 countries with production facilities in Denmark Hungary France China and the US and serves hospitals institutions wholesalers retailers and direct-to-consumer channels primarily in Europe North America and emerging markets. Recent developments include the presentation of its Impact4 five-year strategy in September 2025 targeting 7-8% organic revenue growth through 2030 solidification of chronic care leadership with new ostomy solutions Luja catheters US bowel care reimbursement from October 2025 and Intibia launch in 2026/27; reorganization into Chronic Care and Acute Care business units announced in August 2025; ongoing integration of the 2021 Atos Medical acquisition finalizing in 2025/26 with DKK 100 million synergies; completion of prior acquisitions like Comfort Medical Hope Medical and Rocky Medical Supply; and Global Operations Plan 7 for gross margin and cash flow improvements.

Company News

  • Coloplast: Turnaround Is Underway, But Upside Is Limited

  • Contrasting Coloplast A/S (OTCMKTS:CLPBY) & Omnicell (NASDAQ:OMCL)

  • Coloplast A/S (CLPBY) Q4 2026 Earnings Call Transcript

  • Coloplast pares back China operations as market recovery remains elusive

  • Coloplast A/S (OTCMKTS:CLPBY) Shares Climb 3.9% – Should You Buy?

  • Coloplast A/S (CLPBY) Q3 2026 Earnings Call Transcript

  • Coloplast expects Kerecis wound-care unit to return to growth in 2027, CFO says

  • Coloplast Might Have Found Its Bottom

  • Coloplast: Went 'BUY' A Bit Early

  • Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript

  • Coloplast A/S (CLPBY) Q4 2026 Guidance Call Transcript

  • Comparing Coloplast A/S (OTCMKTS:CLPBY) & Bluejay Diagnostics (NASDAQ:BJDX)

  • Coloplast: The Market Is Throwing Away A High-Quality Compounder

  • Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

  • Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

  • Coloplast appoints Gavin Wood as new CEO

  • CLPBY or PEN: Which Is the Better Value Stock Right Now?

  • Reviewing OPKO Health (NASDAQ:OPK) and Coloplast A/S (OTCMKTS:CLPBY)

  • Coloplast A/S - Updated Financial Calendar 2025-26

  • Coloplast A/S (OTCMKTS:CLPBY) Shares Gap Down – What’s Next?